Aditxt, Inc. (ADTX) - Dilution Analysis

10-Q filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-27 | Outstanding: 904,468 → 33,498

S-3 filing: This prospectus relates to the offer and resale by the Selling Stockholders of up to 148,278,228 shares of Common Stock issuable upon the exercise of the Warrants.

10-K filing | 0.9M shares outstanding

8-K filing: Aditxt, Inc. acquired Ignite Proteomics, LLC by issuing 36,000 shares of newly created Series A-2 Convertible Preferred Stock to IMAC Holdings, Inc. and other investors. ($36.0M proceeds)

8-K filing: Stock split 1-for-113 | Outstanding: 2,431,152 → 21,515

8-K filing: Aditxt, Inc. issued senior notes to accredited investors for $800,000 and purchased a senior subordinated convertible note and warrant of Evofem Biosciences, Inc. for $925,000. ($0.93M proceeds)

8-K filing: Aditxt, Inc. issued a warrant to a Consultant to purchase up to 600,000 shares of the Company's common stock at an exercise price of $2.00 per share.

S-1 filing: This S-1 filing relates to the resale of up to 50,000,000 shares of common stock by Seven Knots, LLC, under a common stock purchase agreement.

8-K filing: Aditxt, Inc. entered into a securities purchase agreement with an accredited investor, issuing a 30% Original Issue Discount Senior Secured Note in the original principal amount of $3,114,285.71 for a purchase price of $2,000,000.

10-Q filing | 2.1M shares outstanding

8-K filing: Aditxt, Inc. purchased a senior subordinated convertible note and a warrant from Evofem Biosciences, Inc. for $1,500,000, with the note convertible into Evofem common stock and the warrant exercisable for Evofem common stock, subject to certain ownership limitations.

10-K filing | 1.2M shares outstanding

8-K filing: Pearsanta, Inc., a subsidiary of Aditxt, Inc., acquired certain patents and intellectual property assets in consideration of the issuance of 200 shares of Series B Convertible Preferred Stock, which will be converted into 1,000 shares of Pearsanta common stock upon a qualifying IPO.

8-K filing: Aditxt, Inc. entered into Amendment No. 5 to the Amended and Restated Merger Agreement with Adifem, Inc. and Evofem Biosciences, Inc., agreeing to Evofem holding a shareholder meeting by September 26, 2025, Aditxt investing an additional $1,500,000 in Evofem by April 7, 2025, and extending the End Date to September 30, 2025. ($4.0M proceeds)

8-K filing: Stock split 1-for-250 | Outstanding: 14,234,210 → 56,936

8-K filing: Aditxt, Inc., Adifem, Inc., and Evofem Biosciences, Inc. amended their merger agreement to extend the End Date from November 29, 2024, to January 31, 2025. ($4.0M proceeds)

10-Q filing | 14.2M shares outstanding

8-K filing: Aditxt, Inc. purchased 2,280 shares of Evofem Biosciences, Inc. Series F-1 Convertible Preferred Stock for $2,280,000. ($2.28M proceeds)

8-K filing: Aditxt, Inc. reports an amendment to its merger agreement with Evofem Biosciences, Inc., including adjustments to equity investment amounts and deadlines. Additionally, a 1-for-40 reverse stock split became effective on October 1, 2024. ($0.46M proceeds)

8-K filing: Aditxt, Inc. issued a senior note for $600,000 and purchased Evofem Biosciences, Inc. Series F-1 Convertible Preferred Stock for $260,000. ($0.26M proceeds)

S-1/A filing: This S-1/A filing describes a proposed offering of up to $150,000,000 of common stock to Seven Knots, LLC, a registered direct offering completed August 9, 2024, and the issuance of warrants to purchase 96,786 shares of common stock.

8-K filing: Aditxt, Inc. amended its merger agreement with Evofem Biosciences, adjusting the timing and amounts of equity investments in Evofem's Series F-1 Preferred Stock. ($1.0M proceeds)

S-3 filing: This is an S-3 filing for Aditxt, Inc. including a common stock purchase agreement with Seven Knots, LLC for up to $150,000,000, details of August 2024 registered direct offering, and a securities exchange agreement.

10-Q filing | 3.6M shares outstanding

8-K filing: Aditxt, Inc. completed the Second Parent Equity Investment and entered into a Securities Purchase Agreement with Evofem Biosciences, Inc., purchasing 500 shares of Evofem's Series F-1 Convertible Preferred Stock for $500,000. ($0.5M proceeds)

8-K filing: Aditxt, Inc. completed an offering on August 9, 2024, selling 188,000 shares of common stock and pre-funded warrants to purchase up to 942,189 shares for gross proceeds of approximately $1.2 million. ($0.0M proceeds)

8-K filing: Aditxt, Inc. entered into a Securities Exchange Agreement with a Holder on August 7, 2024, to exchange Pre-Funded Warrants for Series C-1 Convertible Preferred Stock and warrants to purchase common stock.

S-3/A filing: Aditxt, Inc. may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $100,000,000.

S-3 filing: Aditxt, Inc. files an S-3 registration statement to offer and sell, from time to time, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $100,000,000.

8-K filing: Aditxt, Inc. entered into a Securities Purchase Agreement to issue and sell a senior note for $625,000, receiving $500,000 in cash proceeds, and issued a warrant to purchase up to 1,250,000 shares of common stock at an initial exercise price of $1.49.

S-1/A filing: This S-1/A filing relates to an offering of common stock by a selling stockholder; the company will not receive any proceeds except for warrant exercise price.

8-K filing: Aditxt, Inc. entered into a Securities Purchase Agreement and issued 328,468 shares of common stock as a commitment fee to investors, and sold senior notes for cash proceeds of $775,000.

10-Q filing | 1.6M shares outstanding

S-1/A filing: This S-1/A filing from Aditxt, Inc. outlines an offering of up to 3,785,569 shares of common stock by selling stockholders. The common stock outstanding prior to this offering is 1,665,214 shares.

8-K filing: Aditxt, Inc. entered into a Securities Purchase Agreement to issue Series C-1 and D-1 Preferred Stock and warrants for common stock, with gross proceeds of approximately $4.2 million, intending to use the net proceeds for obligations and general corporate purposes; also, the company filed Certificate of Designations for Series C-1 and D-1 Preferred Stock. ($8.4M proceeds)

10-K filing | 1.7M shares outstanding

8-K filing: Aditxt, Inc. entered into an Arrangement Agreement with Adivir, Inc. and Appili Therapeutics, Inc., pursuant to which Adivir will acquire all of the issued and outstanding Class A common shares of Appili in exchange for cash consideration and Aditxt common stock.

8-K filing: Aditxt, Inc. entered into the Third Amendment to the Merger Agreement, modifying terms related to the acquisition of Evofem Biosciences, Inc., including the assignment of notes and an equity investment into Evofem. ($3.5M proceeds)

S-1/A filing: This S-1/A filing from 2024-02-14 details an offering of up to 3,785,569 shares of common stock by selling stockholders. The company will not receive any proceeds from the sale of these shares, except for warrant exercise prices. As of February 12, 2024, there are 1,665,214 shares of common stock outstanding.

8-K filing: Aditxt, Inc. issued 6,000 shares of Series B-1 Convertible Preferred Stock to the agent of certain secured creditors of Brain Scientific, Inc. in consideration for the assignment of rights under an Asset Purchase Agreement, and filed a Certificate of Designations for the Series B-1 Preferred Stock.

S-1/A filing: S-1/A filing for common stock offering by selling stockholder.

8-K filing: Aditxt, Inc. issued 296,296 shares of its common stock to an investor on January 17, 2024, pursuant to a settlement agreement. ($1.6M proceeds)

S-1 filing: This S-1 filing registers shares of common stock to be offered by selling stockholders.

8-K filing: Aditxt, Inc. entered into a First Amendment to the Asset Purchase Agreement with Pearsanta, Inc. and MDNA Life Sciences, Inc., removing the Upfront Working Capital Payment and the Closing Working Capital Payment and increasing the maximum amount of payments under the Transition Services Agreement from $2.2 million to $3.2 million.

8-K filing: Aditxt, Inc. closed a private placement on January 4, 2024, issuing pre-funded warrants and common warrants, and entered into a settlement agreement to issue shares of common stock to settle an action, with net proceeds from the private placement expected to be approximately $5.5 million.

8-K filing: Aditxt, Inc. entered into an Exchange Agreement with a Noteholder to exchange a secured promissory note for 2,625 shares of Series B-2 Convertible Preferred Stock.

8-K filing: Aditxt, Inc. entered into an Exchange Agreement with holders of Evofem Series F-1 Convertible Preferred Stock to exchange their shares for Aditxt's Series A-1 Convertible Preferred Stock, and filed a Certificate of Designation for the Series A-1 Preferred Stock.

8-K filing: Aditxt, Inc. issued 70,000 shares of its common stock to an independent consultant in consideration for business advisory services.

8-K filing: Aditxt, Inc. entered into an Asset Purchase Agreement with Pearsanta, Inc. and MDNA Life Sciences, Inc., where Pearsanta will acquire certain intellectual property and other specified assets relating to MDNA's early cancer detection platform. The consideration includes 50,000 shares of Aditxt's common stock and warrants to purchase 50,000 shares of Aditxt's common stock.

8-K filing: Aditxt, Inc. entered into a Merger Agreement with Adicure, Inc. and Evofem Biosciences, Inc., where Evofem will merge into a subsidiary of Aditxt, and Aditxt issued secured and unsecured notes in connection with an Assignment Agreement.

10-Q filing | 0.4M shares outstanding

S-1 filing: The filing relates to a resale of up to 264,516 shares of common stock by selling stockholders, consisting of shares issuable upon exercise of warrants, conversion of a secured promissory note, and commitment shares.

RW filing: The Registrant is requesting to withdraw the Registration Statement because it has elected not to pursue the sale of securities pursuant to the Registration Statement at this time and confirms that no securities were sold in connection with the offering contemplated by the Registration Statement.

S-1 filing: The selling stockholders are offering on a resale basis an aggregate of up to 2,060,000 shares of common stock, consisting of shares issuable upon exercise of pre-funded warrants, warrants, and placement agent warrants.

8-K filing: Aditxt, Inc. completed a private placement on September 6, 2023, issuing pre-funded warrants to purchase up to 1,000,000 shares of common stock and common warrants to purchase up to 1,000,000 shares of common stock, with net proceeds expected to be approximately $9 million.

8-K filing: Stock split 1-for-40 | Outstanding: 7,610,739 → 190,268

10-Q filing | 7.6M shares outstanding

8-K filing: Aditxt, Inc. issued a secured promissory note for $2,625,000 resulting in gross proceeds of $1,750,000 and issued 691,106 shares of common stock as a commitment fee to the investor, with an agreement to issue an additional 402,644 shares within 120 days. ($1.75M proceeds)

8-K filing: Aditxt, Inc. issued 156,250 shares of its common stock as a commitment fee to an investor in connection with a Securities Purchase Agreement where the company issued a secured promissory note in the principal amount of $375,000 resulting in gross proceeds to the Company of $250,000.

S-1 filing: S-1 filing for a best-efforts offering of common stock, warrants, and pre-funded warrants.

10-Q filing | 6.8M shares outstanding

8-K filing: Aditxt, Inc. completed a private placement offering, selling pre-funded warrants to purchase up to 1,585,350 shares of common stock at $1.219 per warrant, with concurrent warrants to purchase two shares of common stock at $0.86 per share, resulting in gross proceeds of approximately $1.9 million. ($1.9M proceeds)

10-K filing | 4.8M shares outstanding

8-K filing: Aditxt, Inc. issued 187,000 shares of its common stock to an independent consultant in consideration for business advisory services, guidance on growth strategies and networking with its clients.

10-Q filing | 4.2M shares outstanding

8-K filing: Aditxt, Inc. received notification from Nasdaq that it regained compliance with listing requirements, completed a public offering of shares and warrants, and previously completed a 1-for-50 reverse stock split. ($20.0M proceeds)

8-K filing: Aditxt, Inc. closed a public offering on September 20, 2022, issuing 1,224,333 shares of common stock, pre-funded warrants to purchase 2,109,000 shares of common stock, and warrants to purchase 3,333,333 shares of common stock, resulting in net proceeds of approximately $18.2 million.

S-1/A filing: S-1/A filing on 2022-09-16 for calculating the registration fee pursuant to Rule 457(g) under the Securities Act related to placement agent warrants.

S-1/A filing: The company is offering up to 1,081,081 shares of common stock, together with warrants to purchase 1,081,081 shares of common stock, as well as pre-funded warrants and placement agent warrants.

S-1/A filing: This S-1/A filing from Aditxt, Inc. details a proposed offering of common stock and warrants for working capital purposes, with H.C. Wainwright & Co., LLC as the placement agent, and includes information about warrants, common stock offerings, and use of proceeds.

8-K filing: Aditxt, Inc. entered into an agreement for the purchase and sale of future receipts with a commercial funding source, selling future trade receipts for gross proceeds of $200,000, and issued a warrant to purchase 1,333,334 shares of common stock.

10-Q filing | 56.8M shares outstanding

8-K filing: Aditxt, Inc. consummated an additional closing on August 11, 2022, issuing and selling $555,555.56 in principal amount of 10% Senior Secured Promissory Notes, 555,556 shares of common stock as commitment fees, and warrants to purchase 2,359,046 shares of the Company's common stock. ($0.5M proceeds)

8-K filing: Aditxt, Inc. entered into a Securities Purchase Agreement for the issuance and sale of $1,477,777.78 in principal amount of 10% Senior Secured Promissory Notes, 1,477,778 shares of common stock as commitment fees, and warrants to purchase up to 6,275,065 shares of common stock, resulting in gross proceeds of $1,330,000.00 before expenses. ($1.33M proceeds)

S-1 filing: The filing is an S-1 form for a best-efforts offering of common stock, pre-funded warrants, and placement agent warrants, with the intention to use the net proceeds for continuing operating expenses and working capital.

8-K filing: Aditxt, Inc. entered into a Second Amendment to the Share Exchange Agreement with AiPharma Group Ltd., removing certain covenants and also previously terminated a securities purchase agreement with an investor to issue and sell 8,333,334 shares of common stock and warrants for gross proceeds of $2.5 million due to the investor's failure to fund. ($2.5M proceeds)

8-K filing: Aditxt, Inc. amended a warrant agent agreement and entered into a letter agreement with a warrant holder to exercise 8,970,947 Series C Warrants at a reduced price of $0.15 per share, resulting in gross proceeds of approximately $1.35 million for the company, and issued new warrants. ($1.35M proceeds)

10-Q filing | 44.7M shares outstanding

8-K filing: Aditxt, Inc. entered into a Forbearance Agreement and Eighth Amendment to Secured Credit Agreement, a Revenue Sharing Agreement, Security Agreements, and an Amendment to the Share Exchange Agreement, which permits the company to amend its Certificate of Incorporation to effect a reverse stock split if necessary to maintain its Nasdaq listing. ($0.5M proceeds)

10-K filing | 44.7M shares outstanding

8-K filing: Aditxt, Inc. will acquire 9.5% of AiPharma Group Ltd. for 4,816,193 shares of Aditxt common stock and $250,000, with a subsequent acquisition of the remaining 90.5% for 39,927,974 shares of Aditxt common stock and another $250,000.

8-K filing: Aditxt, Inc. closed a public offering of 16,575,000 units at $1.05 per unit on December 6, 2021, resulting in net proceeds of approximately $16.2 million. ($17.4M proceeds)

10-Q filing | 26.9M shares outstanding

8-K filing: Aditxt, Inc. closed a public offering of 2,833,333 shares of common stock at a price of $1.50 per share, resulting in net proceeds of approximately $3.91 million. ($4.25M proceeds)

8-K filing: Aditxt, Inc. completed a registered direct offering of 4,583,334 shares of common stock at a purchase price of $2.40 per share on August 31, 2021, and as a result of the registered direct offering and conversion of a note, there were 21,090,935 shares of the Company's common stock issued and outstanding as of the filing date. ($11.0M proceeds)

8-K filing: Aditxt, Inc. sold 4,583,334 shares of common stock at $2.40 per share in a private placement, generating gross proceeds of approximately $11.0 million and net proceeds of $10.1 million to fund a loan and for general corporate purposes. ($11.0M proceeds)

10-Q filing | 14.7M shares outstanding

S-3 filing: Aditx Therapeutics, Inc. may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $100,000,000.

10-Q filing | 14.5M shares outstanding

10-K filing | 14.1M shares outstanding

8-K filing: The Company entered into an Employment Agreement with Mr. Amro Albanna, the Chief Executive Officer and President of the Company, which includes a grant of 300,000 shares of restricted stock.

S-1 filing: This prospectus relates to the sale from time to time of up to 6,798,122 shares of common stock held by the selling stockholders.

8-K filing: Aditx Therapeutics, Inc. entered into a Securities Purchase Agreement for a $6,000,000 Senior Secured Convertible Promissory Note and will issue warrants to purchase up to 800,000 shares of common stock to an institutional accredited investor.

8-K filing: Aditx Therapeutics, Inc. entered into a Consulting Agreement with Salveo Diagnostics, Inc., where Salveo will establish a diagnostic laboratory for the Company, and in consideration, the Company will issue Salveo up to 650,000 shares of common stock upon completion of certain milestones.

10-Q filing | 12.3M shares outstanding

8-K filing: Aditx Therapeutics, Inc. consummated an underwritten public offering of 2,400,000 units, each consisting of one share of common stock, one Series A-1 warrant, and one Series B-1 warrant, at a price of $4.00 per unit, resulting in gross proceeds of approximately $9.6 million before deducting underwriting discounts and commissions. ($9.6M proceeds)

8-K filing: Aditx Therapeutics, Inc. filed a Certificate of Designations, Preferences and Rights for Series A Convertible Preferred Stock, designating 1,250,000 shares.

S-1 filing: This is an S-1 filing for an initial public offering of common stock and warrants.

10-Q filing | 7.0M shares outstanding

8-K filing: The company completed an IPO and sold 1,226,668 units, each consisting of one share of common stock, one Series A warrant, and one Series B warrant.

S-1/A filing: This is an initial public offering of units of securities of Aditx Therapeutics, Inc., with each Unit consisting of one share of common stock, one Series A warrant, and one Series B warrant.

S-1/A filing: Initial public offering of 1,333,334 units, each consisting of one share of common stock, one Series A warrant exercisable at $9.00, and one Series B warrant exercisable at $11.25.

S-1/A filing: The company is engaged in a public offering of up to 1,900,000 Units, each Unit consisting of one share of common stock and one Warrant to purchase one share of Common Stock.

S-1/A filing: Aditx Therapeutics, Inc. is offering 1,900,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, in an initial public offering.

S-1/A filing: This is an initial public offering of units of securities of Aditx Therapeutics, Inc., with each unit consisting of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.875.

S-1/A filing: This is an initial public offering of units of securities of Aditx Therapeutics, Inc. Each Unit consists of (a) one share of our common stock, and (b) one warrant to purchase one share of our common stock at an exercise price equal to $6.875 from the date that is six-months from the date of issuance until the fifth anniversary of the issuance date. The public offering price per Unit is $5.50.

S-1/A filing: Initial public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $5.50 per unit.

S-1/A filing: This is an S-1/A filing for an initial public offering of units of securities of Aditx Therapeutics, Inc., with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

S-1 filing: Aditx Therapeutics, Inc. is offering 1,900,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.875, in an initial public offering.